SPOTLIGHT -
Defining Chronic Graft vs Host Disease (GvHD)
Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.
Read More
Novel Agents in Acute GvHD
Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.
Steroid Refractory Acute GvHD and REACH Trials
An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.
Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options
Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.
Future of Acute GvHD Prevention
A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.
Clinical Implications of the Phase III BMT CTN 1703 Trial
Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice
Regimens Used for GvHD Prevention
A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.
An Overview of Graft vs Host Disease (GvHD)
Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
